Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Crescita Therapeutics Inc CRRTF

Primary Symbol: T.CTX

Healthcare

Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial... see more

Add To Watchlist

Recent & Breaking News (TSX:CTX)

Crescita Therapeutics to Host Investor Webcast on July 24, 2019

Canada NewsWire July 11, 2019

Crescita Therapeutics Inc. Receives 2nd Instalment of Up-Front Payment of Euro1.25 Million Following First Commercial Sale of Pliaglis by Cantabria in Italy

Canada NewsWire July 4, 2019

Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

Canada NewsWire June 26, 2019

Crescita Therapeutics Inc. Announces Intention to Make Normal Course Issuer Bid

Canada NewsWire June 17, 2019

Crescita to Present at the 9th Annual LD Micro Invitational in Los Angeles, California

Canada NewsWire May 30, 2019

Crescita Therapeutics Engages Bristol Capital to Provide Investor Relations and Communications Services

Canada NewsWire May 29, 2019

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Canada NewsWire May 15, 2019

Crescita Therapeutics Reports 2019 First Quarter Results

Canada NewsWire May 15, 2019

Crescita Therapeutics Strengthens Leadership Team with New Vice-President in Aesthetic and Cosmeceutical Business Unit

Canada NewsWire May 7, 2019

Crescita Therapeutics Signs Pliaglis® Out-Licensing Agreement with Cantabria Labs for Euro2.5M Upfront After Reacquiring Rest-of-World Rights

Canada NewsWire April 25, 2019

Crescita Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference in Toronto

Canada NewsWire April 17, 2019

Crescita Therapeutics Reports Fourth Quarter and Fiscal 2018 Results Record Annual Revenue of $16.6M and Adjusted EBITDA of $1.5M Strong Royalties and Sales Milestones

Canada NewsWire March 21, 2019

Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra’s Dermatology Product Portfolio

GlobeNewswire February 4, 2019

U.S. FDA Approves Removal of "Not for Home Use" Label Restriction for Pliaglis®

Canada NewsWire December 17, 2018

Crescita Therapeutics™ Reports 2018 Third Quarter Results Strong Royalty Revenue and Achievement of First Pliaglis US Sales Milestone Positive Adjusted EBITDA of $0.8M

Canada NewsWire November 9, 2018

Crescita Reinvigorates Skincare Line Leveraging its MMPE™ Technology and Becomes One of the First Companies Worldwide to Release Anti-Ageing Formulation Using ECOBIOTYS®

Canada NewsWire November 8, 2018

Crescita's Patented Delivery Technologies Demonstrate Enhanced Skin Permeation of Cannabidiol

PR Newswire October 15, 2018

Crescita Therapeutics™ Reports 2018 Second Quarter Results

Canada NewsWire August 10, 2018

Crescita Therapeutics Inc. to Present at The MicroCap Conference on June 21st in Toronto

Accesswire June 19, 2018

Crescita Therapeutics™ Announces Director Election Results of its Annual General Meeting

Canada NewsWire June 13, 2018